Treatment of Inflammatory Diseases Using Placental Stem Cells
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 12/030,161, filed Feb 12, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,916,146 | Treatment of Inflammatory Diseases Using Placental Stem Cells In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | ||
| US 11,723,930 | Treatment of Inflammatory Diseases Using Placental Stem Cells In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | ||
| US 8,460,650 | Treatment of Inflammatory Diseases Using Placental Stem Cells Lapsed Jun 11, 2025 on the fee record Ended Jun 11, 2025 · High confidence | Celeniv Pte. Ltd. | Lapsed Jun 11, 2025 on the fee record | Ended Jun 11, 2025 | High confidence | |
| US 8,753,883 | Treatment of Psoriasis Using Placental Stem Cells Lapsed Jun 17, 2026 on the fee record Ended Jun 17, 2026 · High confidence | Celeniv Pte. Ltd. | Lapsed Jun 17, 2026 on the fee record | Ended Jun 17, 2026 | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Celeniv Pte. Ltd..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.